SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika inc. (T.ISA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: teevee who wrote (2)11/6/2001 7:32:14 PM
From: teevee  Read Replies (1) of 23
 
newswire.ca

Isotechnika Appoints Transplant Physician as Vice-President of Medical Affairs

Trades on the Toronto Stock Exchange - (TSE:ISA)

EDMONTON, Nov. 6 /CNW/ - Isotechnika President & COO Dr. Randall Yatscoff
today announced the appointment of Dr. Anthony (Tony) Broski to the newly
created position of Vice-President of Medical Affairs.
Dr. Yatscoff says: "Dr. Broski brings considerable expertise in
transplantation medicine and research to our immunosuppressive drug research
team. He has also coordinated a number of clinical trials which will
facilitate the development of our lead drug ISA(TX)247 which is presently in
Phase II trials in renal (kidney) transplantation, psoriasis and rheumatoid
arthritis."
Dr. Broski is a transplant physician with extensive experience in both
internal medicine and nephrology. He has been Director of Dialysis Programs
for Northern Alberta and the Niagara Region serving 750 dialysis patients. He
has been an assistant or adjunct professor at three Canadian Universities -
McMaster in Hamilton, the University of Western Ontario in London and the
University of Alberta.
He played a major role in organ transplantation in the Niagara Region. He
started the area's first post op clinic for kidney transplant patients. He has
also been active in promoting organ donor awareness throughout his career.
Dr. Broski says: "Working with so many people on dialysis over the years
has given me a first hand insight into how important transplantation is in
changing their lives. I'm excited to be working with highly talented people at
Isotechnika in developing a drug which may play an equally important role in
improving the lives of transplant patients."
Dr. Yatscoff says: "Dr. Broski will be responsible for dealing with the
FDA, Health Canada and other government regulatory agencies."

About Isotechnika
Isotechnika is a life-sciences company headquartered in Edmonton,
Alberta, Canada. The Company's lead drug is ISA(TX)247, a novel platform
designed to prevent organ rejection following transplantation as well as the
treatment of autoimmune diseases. The drug is currently in Phase II trials at
15 transplantation centres throughout North America. Isotechnika also globally
markets and distributes its internally developed breath-test diagnostic
product line. One of these products, the Helikit, is regarded as the gold
standard for the diagnosis of ulcers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News